Status:
COMPLETED
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
Lead Sponsor:
Roxane Laboratories
Conditions:
Seizures
Epilepsy
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The objective of this study was to assess bioequivalence of a potential generic 600 mb oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, ...
Eligibility Criteria
Inclusion
- No clinically significant abnormal finding on the physical examination, medical history, or clinical laboratory results at screening.
Exclusion
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with any known enzyme altering drugs.
- History of allergic or adverse response to oxcarbazepine or any other comparable or similar product.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2004
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00618046
Start Date
November 1 2004
End Date
November 1 2004
Last Update
January 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bio-Kinetics Clinical Applications, Inc .
Springfield, Missouri, United States, 658902